GLP-1 medications have multiple different mechanisms in the body that help with diabetes and weight loss, including: Increasing the amount of insulin made by the pancreas , which helps control blood sugar in patients with diabetes Decreasing the amount of excess sugar made by the pancreas , which helps control blood sugar in patients with diabetes Slowing down digestion from the stomach , which results in feeling full for longer after eating Signaling to your brain that you are full after eating , which helps suppress appetite and control cravings Tirzepatide contains an extra mechanism of action that other GLP-1 medications do not, known as GIP (glucose-dependent insulinotropic polypeptide) agonism
April 2024
Analytical testing supports identity and quality assessment, but it does not convert a research peptide into an approved medication
GLP-1 receptors are found in non-neoplastic pancreatic islet cells, duodenal glands, stomach, breast tissue, lung and kidney vasculature, and brain tissue
But patients will need careful monitoring to make sure the weight they lose is mostly fat, not muscle
Related Reporting on Weight Management Options For readers exploring the broader weight management landscape, the following third-party reporting provides additional context on different product categories: Analysis of telehealth GLP-1 supplier options - Third-party reporting on compounded semaglutide access through telehealth platforms
00656-2/asset/35b48abc-e313-46be-9a87-b6727032b3d4/main.assets/gr1_lrg.jpg)
